On Wednesday, Shares of QUALCOMM, Inc. (NASDAQ:QCOM), lost -0.23% to $61.18.
Siklu Inc., declared that it has closed $18 million in Series-D funding to further accelerate the company’s already impressive growth and market leadership. The new investor in this round Sercomm Corporation (5388.TW), was joined by existing investors Argonaut Private Equity, Evergreen Venture Partners, DFJ Tamir Fishman Ventures, Qualcomm Ventures (QCOM), The Tamares Group and Amiti Ventures.
“Siklu approaches network connectivity in an entirely different way, packing cutting edge technology into mass market products. We believe in the company’s potential to be a bellwether of change for the future of wireless networks,” said James Wang, President and CEO, Sercomm. “The planned partnership we are building with Siklu will enable both our companies to enter new markets, which are predictable to grow exponentially”.
According to research firm MarketsandMarkets, the global millimeter wave technology market is predictable to grow by 42.7% CAGR to $1.7 billion by 2020. Siklu is poised to capture this market through a range of competitively priced solutions in areas such as video surveillance, Wi-Fi backhaul and access to residential Multi-Dwelling-Units (MDU). Siklu’s mmWave solutions and technology already provide thousands of fiber extensions for 3G/LTE telecommunication networks and business connectivity.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products.
Shares of AngloGold Ashanti Limited (ADR) (NYSE:AU), inclined 10.81% to $7.48, during its last trading session.
AngloGold Ashanti, said it generated $71m of free cash flow in the second quarter with production and costs beating guidance on the back of another strong performance from its international mines and a recovery from its South African operations.
AngloGold Ashanti has responded to lower gold prices by cutting overhead expenditure by more than two-thirds since the end of 2012, whilst lowering all-in sustaining costs (AISC) by about a quarter over the same period. The group has introduced two new, low-cost mines, sold or closed higher-cost assets and removed unprofitable ounces from its portfolio. The company also sold its Cripple Creek & Victor mine (CC&V) in the US for $820m in June of this year to reduce net debt, and is now intensifying efficiency efforts to complement the cost benefit it receives from weakening local currencies and plummeting oil prices.
The company’s international mines saw AISC 17% lower than the second quarter of 2014 at $844/oz. Standout performances were delivered by the Geita and the South American mines in Brazil and Argentina, while the contribution from Tropicana and Kibali reflected their full ramp-up. Work continues on a brownfield project options to extend life, improve production or enhance efficiencies, at the Geita, Serra Grande, Siguiri and Sunrise Dam mines.
AngloGold Ashanti Limited operates as a gold mining and exploration company. It also produces silver, uranium oxide, copper, molybdenum, and sulphur. The company has 20 operations and exploration projects in South Africa, Continental Africa, Australasia, and the Americas. AngloGold Ashanti Limited was founded in 1944 and is headquartered in Johannesburg, South Africa.
Finally, Immunomedics, Inc. (NASDAQ:IMMU), ended its last trade with -4.71% loss, and closed at $1.82.
Immunomedics, stated financial results for the fourth quarter and fiscal year ended June 30, 2015. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
Fourth Quarter Fiscal 2015 Results
Total revenues for the fourth quarter of fiscal year 2015, which ended on June 30, 2015, were $2.4 million as contrast to total revenues of $1.2 million for the same quarter last fiscal year. The enhance of $1.2 million in total revenues this quarter was primarily due to a $1.0 million license fee revenue earned upon reaching a clinical milestone in the Company’s Partnership Agreement, as amended, with Bayer (formerly Algeta ASA). There was no license fee revenue recorded in the same quarter last fiscal year.
Total costs and expenses for the current quarter were $13.6 million, in contrast to $13.1 million for the same period in 2014, representing enhance of $0.5 million, or 4%. This enhance was driven primarily by $1.1 million higher research and development expenses from raised clinical trial cost for the Phase 3 PANCRIT-1 registration study of yttrium-90-labeled clivatuzumab tetraxetan for the therapy of patients with advanced pancreatic cancer, and raised product development and manufacturing expenses related to the expansion of clinical studies for the two antibody-drug conjugate (ADC) programs. The enhance in research and development expenses was partially offset by $0.4 million reduced general and administrative costs mainly from reduced legal and professional fees.
Interest expense this quarter related to the 4.75% Convertible Senior Notes was $1.4 million, counting the amortization of $0.2 million debt issuance costs. There was no interest expense for the same quarter last fiscal year.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
